In a study funded by the charity Leukemia & Lymphoma Research published in the leukemia journal Blood (09 Jan 2012) scientists discovered a gene variation which can have a large effect on how well treatment works in patients with a rare type of blood cancer. Occurring in 20% of the population, the CD95 gene is one of the genes involved in controlling the death of cells in the body. According to the researchers, having an abnormal version of the CD95 gene may also affect survival rates for other types of cancer like lymphoma, breast and prostate cancer.
